Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA +1.30%30 Equity-to-Asset is 0.89 as of Dec. 2025, which is at its 10-year median of 0.89. GuruFocus rates ASX:ILA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Island Pharmaceuticals ranks better than 81.5% on this metric.
Island Pharmaceuticals (ASX:ILA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Island Pharmaceuticals Equity-to-Asset Related Terms
Island Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Island Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ILA vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's Equity-to-Asset falls into.
Island Pharmaceuticals Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Island Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Island Pharmaceuticals (ASX:ILA) has a Equity-to-Asset of 0.89 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Island Pharmaceuticals and its competitors. This is near median its historical median of 0.89. Over the past decade, Island Pharmaceuticals' Equity-to-Asset has ranged from 0.36 to 0.98. According to the industry distribution chart, Island Pharmaceuticals ranks #262 out of 1416 companies in the Biotechnology industry, placing it in the top 18.5%.
Is Island Pharmaceuticals' Equity-to-Asset too high?
Island Pharmaceuticals' current Equity-to-Asset of 0.89 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. Island Pharmaceuticals' value of 0.89 is 30.9% above this industry median. Based on the distribution chart, Island Pharmaceuticals ranks #262 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #262 out of 1416 companies for Equity-to-Asset. This places Island Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Island Pharmaceuticals' value of 0.89 is 30.9% above this benchmark. Historically, Island Pharmaceuticals' own Equity-to-Asset has ranged from 0.36 to 0.98 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.68, Island Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Island Pharmaceuticals's current Equity-to-Asset of 0.89 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current Equity-to-Asset is 0.89, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Equity-to-Asset of 0.89. The current Equity-to-Asset is 0.89, which is near median its 10-year median of 0.89 and 30.9% above the Biotechnology industry median of 0.68. Island Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Equity-to-Asset is 0.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
30GF Score
Get the complete analysis for ASX:ILA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
